Please sign in so that we can notify you about a reply
Indications/Uses
For the treatment of mild to moderate severe somatic and neuritic pains such as headache, migraine, traumatic pain, post-partum pain, post-operative pains, dental pain and dysmenorrhea.
Dosage/Direction for Use
Take one (1) capsule every eight (8) hours. Preferably taken with food. Treatment should not be continued for longer than seven days.
Or as prescribed by the physician.
Or as prescribed by the physician.
Administration
Should be taken with food.
Contraindications
Mefenamic Acid is contraindicated in inflammatory bowel disease and in patients suffering from peptic and intestinal ulceration and in patients with renal or hepatic impairment.
Warnings
Gastrointestinal discomfort, diarrhea or gas constipation, nausea vomiting, drowsiness and dizziness have been observed. Signs of hemolytic anemia should be watched in cases when the drug is taken for a prolonged period of time, as in all inhibitors of prostaglandin synthesis. Mefenamic acid can affect platelet function. In large doses, the drug may induced grand mal convulsions hence, it is suggested to avoid this in epileptics.
Special Precautions
In patients suffering from dehydration and renal diseases, particularly the elderly. Concurrent therapy with other plasma protein binding drugs may decessitate a medication in dosage. In the case of anticoagulants, the dose of anticoagulant may need to be reduced. The safety of Mefenamic Acid in pregnancy and in children under 14 years of age has not been established.
Adverse Reactions
Hepatic function disorders; transient increase in serum transaminase levels. Mild fever, malaise & liver tenderness. Nausea, anorexia, vomiting, diarrhea & aggravation of peptic ulcer.
Storage
Store at temperatures not exceeding 30°C.
MedsGo Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Features
Dosage
500 mg
Ingredients
- Mefenamic Acid
Packaging
Tablet 100's
Generic Name
Mefenamic Acid
Registration Number
DRP-1837
Classification
Prescription Drug (RX)
Product Questions
Questions
